ATE230990T1 - Enantiomere hydroxylierte xanthinverbindungen - Google Patents

Enantiomere hydroxylierte xanthinverbindungen

Info

Publication number
ATE230990T1
ATE230990T1 AT93908327T AT93908327T ATE230990T1 AT E230990 T1 ATE230990 T1 AT E230990T1 AT 93908327 T AT93908327 T AT 93908327T AT 93908327 T AT93908327 T AT 93908327T AT E230990 T1 ATE230990 T1 AT E230990T1
Authority
AT
Austria
Prior art keywords
compounds
enantiomeric
xanthine compounds
hydroxylated
hydroxylated xanthine
Prior art date
Application number
AT93908327T
Other languages
English (en)
Inventor
James A Bianco
Paul Woodson
David Porubek
Jack Singer
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Application granted granted Critical
Publication of ATE230990T1 publication Critical patent/ATE230990T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
AT93908327T 1992-03-04 1993-03-01 Enantiomere hydroxylierte xanthinverbindungen ATE230990T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84635492A 1992-03-04 1992-03-04
US92666592A 1992-08-07 1992-08-07
PCT/US1993/002304 WO1993017684A2 (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds

Publications (1)

Publication Number Publication Date
ATE230990T1 true ATE230990T1 (de) 2003-02-15

Family

ID=27126630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93908327T ATE230990T1 (de) 1992-03-04 1993-03-01 Enantiomere hydroxylierte xanthinverbindungen

Country Status (17)

Country Link
US (8) US5652243A (de)
EP (1) EP0584347B1 (de)
JP (4) JP2753395B2 (de)
KR (1) KR950700066A (de)
CN (1) CN1040646C (de)
AT (1) ATE230990T1 (de)
AU (1) AU669702B2 (de)
CA (1) CA2112239C (de)
CZ (1) CZ212394A3 (de)
DE (1) DE69332634T2 (de)
DK (1) DK0584347T3 (de)
ES (1) ES2191013T3 (de)
IL (1) IL104943A (de)
NO (1) NO943263L (de)
NZ (1) NZ247038A (de)
PT (1) PT584347E (de)
WO (1) WO1993017684A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5795897A (en) * 1992-11-18 1998-08-18 Cell Therapeutics, Inc. Oxohexyl methylxanthine compounds
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
WO1995019171A1 (en) * 1994-01-14 1995-07-20 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
CA2190511A1 (en) * 1994-05-16 1995-11-23 J. Peter Klein Asymmetric synthesis of chiral secondary alcohols
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6136964A (en) * 1996-03-19 2000-10-24 Cell Therapeutics, Inc. Mammalian lysophosphatidic acid acyltransferase
CA2291516A1 (en) * 1997-05-27 1998-12-03 Cell Therapeutics, Inc. Mammalian lysophosphatidic acid acyltransferase
WO1999018942A1 (en) * 1997-10-10 1999-04-22 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
US6111329A (en) * 1999-03-29 2000-08-29 Graham; Gregory S. Armature for an electromotive device
AU777869B2 (en) * 1999-09-24 2004-11-04 Shire Canada Inc. Method for the treatment or prevention of viral infection using nucleoside analogues
FR2804867B1 (fr) * 2000-02-15 2002-09-20 Hoechst Marion Roussel Inc Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
AU9486901A (en) 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
DK2295081T3 (en) 2001-06-26 2019-02-18 Amgen Inc Antibodies to OPGL
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
MEP32508A (en) 2002-09-06 2010-10-10 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
PT1781657E (pt) 2004-02-14 2013-05-23 Glaxosmithkline Ip Dev Ltd Medicamentos com actividade no receptor hm74a
WO2006074051A2 (en) * 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
SI1912991T1 (sl) 2005-08-10 2011-03-31 Glaxosmithkline Llc One Franklin Plaza Derivati ksantina kot selektivni hm74a agonisti
US20080059313A1 (en) * 2006-08-30 2008-03-06 Oblong John E Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair
BRPI0907970B1 (pt) * 2008-02-29 2020-06-30 The Procter & Gamble Company composição para tratamento dos cabelos ou pelos e método para aumentar o diâmetro dos cabelos ou pelos
US9133062B2 (en) 2012-11-21 2015-09-15 Corning Incorporated Method of firing cordierite bodies
US10123966B2 (en) 2013-05-16 2018-11-13 The Procter And Gamble Company Hair thickening compositions and methods of use
CN103880861B (zh) * 2014-02-21 2016-02-03 温州医科大学 一种作用于FGF受体的4,6-二甲基-噁唑并[5,4-d]嘧啶-5,7（4H,6H）-二酮衍生物
CN105566324B (zh) * 2014-10-09 2020-04-03 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用
EP3205652B1 (de) * 2014-10-09 2022-03-09 Guangdong Raynovent Biotech Co., Ltd. Hydroxylpurinverbindungen und anwendungen davon
US10399981B2 (en) 2015-10-29 2019-09-03 Guangdong Raynovent Biotech Co., Ltd. Crystal form A of 7-(cyclopropylmethyl)-1-(((cis )-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422107A (en) * 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
US3373433A (en) * 1964-12-16 1968-03-12 Sylvania Electric Prod Dual linear/circular polarization spiral antenna
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4515795A (en) * 1968-11-25 1985-05-07 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
DE3817955A1 (de) * 1988-05-27 1989-11-30 Hoechst Ag Tnf-inhibitor enthaltendes arzneimittel
DE3942871A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag R-(-)-1-(5-hydroxyhexyl)-3-methyl-7-propylxanthin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel
DE3942872A1 (de) * 1989-12-23 1991-06-27 Hoechst Ag Verfahren zur enantioselektiven darstellung von ((omega)-1)-hydroxyalkylxanthinen
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
EP0573617A1 (de) * 1991-05-24 1993-12-15 Fred Hutchinson Cancer Research Center Modulation der zellulären reaktion auf externe stimuli
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.

Also Published As

Publication number Publication date
CA2112239C (en) 2000-05-09
US5652243A (en) 1997-07-29
US5792772A (en) 1998-08-11
DE69332634T2 (de) 2003-05-08
EP0584347B1 (de) 2003-01-15
NO943263L (no) 1994-11-02
US5629315A (en) 1997-05-13
AU3919093A (en) 1993-10-05
IL104943A (en) 1998-12-27
WO1993017684A2 (en) 1993-09-16
WO1993017684A3 (en) 1993-11-25
NZ247038A (en) 1995-02-24
CN1085557A (zh) 1994-04-20
JP2753395B2 (ja) 1998-05-20
DE69332634D1 (de) 2003-02-20
US5739138A (en) 1998-04-14
IL104943A0 (en) 1993-07-08
AU669702B2 (en) 1996-06-20
JP2002087961A (ja) 2002-03-27
ES2191013T3 (es) 2003-09-01
US5965564A (en) 1999-10-12
NO943263D0 (no) 1994-09-02
US5620984A (en) 1997-04-15
JPH06509584A (ja) 1994-10-27
CA2112239A1 (en) 1993-09-16
PT584347E (pt) 2003-06-30
EP0584347A4 (de) 1995-04-26
CZ212394A3 (en) 1995-09-13
US5621102A (en) 1997-04-15
EP0584347A1 (de) 1994-03-02
KR950700066A (ko) 1995-01-16
JP2004002467A (ja) 2004-01-08
US5612349A (en) 1997-03-18
DK0584347T3 (da) 2003-02-24
JPH08259565A (ja) 1996-10-08
CN1040646C (zh) 1998-11-11

Similar Documents

Publication Publication Date Title
DK0584347T3 (da) Enantiomere hydroxylerede xanthinforbindelser
PT92153A (pt) Processo para a preparacao de derivados de 1,4-diazepina e de composicoes farmaceuticas que os contem
NZ236589A (en) A-nor-steroid-3-carboxylic acid derivatives and pharmaceutical compositions
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
DK162090C (da) 3-acyl-2-oxindol-1-carboxamid-forbindelser samt 2-oxindol-1-carboxamid-forbindelser til anvendelse som mellemprodukter
ES378823A1 (es) Un metodo para preparar un compuesto seleccionado del grupoque consta de bases de 1-aminobenzocicloalcano.
BG92804A (bg) 4-бензоилизоксазолови производни
CO5050332A1 (es) Composiciones fungicidas que comprenden 2-metoxibenzofenonas
YU47204B (sh) Derivati didehidro-vitamina d3
MY105328A (en) Blocking agents of edrf effect or formation for the treatment of shock.
ES2104090T3 (es) Nuevas 3',5'-di-t-butil-4'-hidroxi-flavonas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
IL107870A0 (en) Pharmaceutical compositions having antidepressant activity comprising pramipexol
ES2174298T3 (es) Derivados de aminotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
SE8703169L (sv) 1-(4-aminofenyl)-4-metyl-7,8-metylendioxi-3,4-dihydro-5h-2,3-bensodiazepin, syraadditionssalter derav samt forfarande for framstellning av densamma
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
ATE66673T1 (de) 2-pyrrolidonderivate, verfahren zur herstellung, pharmazeutische zusammensetzungen und anwendung.
ES2039292T3 (es) Derivados de piranobenzoxadiazol, preparacion de los mismos, utilizacion y compuestos que los comprenden.
AR241243A1 (es) Nuevos derivados de 1-fenil-1-oximino-haloalquilo procedimiento para su preparacion y composiciones que los contienen.
FR2381034A1 (fr) Compositions pharmaceutiques analgesiques et anti-inflammatoires a base de 1,3,5-triazine
DK157131C (da) Carmamyloxybenzhydrolderivater, farmaceutisk praeparat samt en fremgangsmaade til fremstilling af dette
MX9303392A (es) Derivados de imidazo benzoxazin-1-ona substituidos y proceso para su preparacion.
FI872997A (fi) Amidderivat.
ES2039284T3 (es) Un procedimiento para preparar derivados de la 1-benzoil-2-oxo-5-alcoxi-pirrolidina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0584347

Country of ref document: EP

REN Ceased due to non-payment of the annual fee